BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update
BioCryst Pharmaceuticals (Nasdaq:BCRX) reported outstanding Q2 2025 financial results, marking the company's best quarter historically. ORLADEYO net revenue reached $156.8 million, up 45% year-over-year, with total revenues of $163.4 million. The company achieved an operating profit of $29.8 million (+239% y-o-y) and non-GAAP operating profit of $57.0 million.
Key highlights include record-breaking new patient prescriptions, increased prescriber base, and lower discontinuation rates. BioCryst made a $50 million debt paydown in July and plans to retire all remaining term debt using proceeds from the sale of its European ORLADEYO business. The company maintains its 2025 ORLADEYO revenue guidance of $580-600 million and expects positive cash flows for the full year.
The rare disease pipeline continues advancing with ORLADEYO granules for children (PDUFA date: December 12, 2025) and expected initial data from BCX17725 and avoralstat programs by year-end.BioCryst Pharmaceuticals (Nasdaq:BCRX) ha riportato risultati finanziari eccezionali per il secondo trimestre del 2025, segnando il miglior trimestre nella storia dell'azienda. I ricavi netti di ORLADEYO hanno raggiunto 156,8 milioni di dollari, con un incremento del 45% rispetto all'anno precedente, e ricavi totali pari a 163,4 milioni di dollari. L'azienda ha ottenuto un utile operativo di 29,8 milioni di dollari (+239% su base annua) e un utile operativo non-GAAP di 57,0 milioni di dollari.
I punti salienti includono un numero record di nuove prescrizioni per pazienti, un aumento della base di prescrittori e tassi di interruzione più bassi. BioCryst ha effettuato un rimborso del debito di 50 milioni di dollari a luglio e prevede di estinguere tutto il debito residuo a termine utilizzando i proventi della vendita della sua attività europea di ORLADEYO. L'azienda conferma la sua previsione di ricavi ORLADEYO per il 2025 tra 580 e 600 milioni di dollari e si aspetta flussi di cassa positivi per l'intero anno.
Il portafoglio di malattie rare continua a progredire con le granuli di ORLADEYO per bambini (data PDUFA: 12 dicembre 2025) e i dati iniziali attesi dai programmi BCX17725 e avoralstat entro la fine dell'anno.
BioCryst Pharmaceuticals (Nasdaq:BCRX) reportó resultados financieros sobresalientes en el segundo trimestre de 2025, marcando el mejor trimestre en la historia de la compañía. Los ingresos netos de ORLADEYO alcanzaron los 156.8 millones de dólares, un aumento del 45% interanual, con ingresos totales de 163.4 millones de dólares. La empresa logró un beneficio operativo de 29.8 millones de dólares (+239% interanual) y un beneficio operativo no-GAAP de 57.0 millones de dólares.
Los aspectos destacados incluyen un récord en nuevas prescripciones para pacientes, una base de prescriptores ampliada y menores tasas de descontinuación. BioCryst realizó un pago de deuda de 50 millones de dólares en julio y planea liquidar toda la deuda a plazo restante con los ingresos de la venta de su negocio europeo de ORLADEYO. La empresa mantiene su guía de ingresos de ORLADEYO para 2025 entre 580 y 600 millones de dólares y espera flujos de caja positivos durante todo el año.
La cartera de enfermedades raras sigue avanzando con los gránulos de ORLADEYO para niños (fecha PDUFA: 12 de diciembre de 2025) y se esperan datos iniciales de los programas BCX17725 y avoralstat para fin de año.
BioCryst Pharmaceuticals (Nasdaq:BCRX)는 2025년 2분기 뛰어난 재무 실적을 보고하며 회사 역사상 최고의 분기를 기록했습니다. ORLADEYO 순매출은 1억 5,680만 달러로 전년 동기 대비 45% 증가했으며, 총 매출은 1억 6,340만 달러를 기록했습니다. 회사는 영업이익 2,980만 달러(전년 대비 239% 증가)와 비-GAAP 영업이익 5,700만 달러를 달성했습니다.
주요 성과로는 신환 처방 건수 최고 기록, 처방 의사 수 증가, 중단율 감소가 포함됩니다. BioCryst는 7월에 5,000만 달러 부채 상환을 완료했으며, 유럽 ORLADEYO 사업 매각 수익을 활용해 남은 모든 장기 부채를 상환할 계획입니다. 회사는 2025년 ORLADEYO 매출 가이던스를 5억 8,000만~6억 달러로 유지하며, 연간 긍정적 현금 흐름을 기대하고 있습니다.
희귀질환 파이프라인은 어린이용 ORLADEYO 과립제(PDUFA 날짜: 2025년 12월 12일)와 BCX17725 및 avoralstat 프로그램의 초기 데이터가 연말까지 발표될 예정이며 계속 진전 중입니다.
BioCryst Pharmaceuticals (Nasdaq:BCRX) a annoncé d'excellents résultats financiers pour le deuxième trimestre 2025, marquant le meilleur trimestre de son histoire. Le chiffre d'affaires net d'ORLADEYO a atteint 156,8 millions de dollars, en hausse de 45 % par rapport à l'année précédente, avec un chiffre d'affaires total de 163,4 millions de dollars. La société a réalisé un bénéfice d'exploitation de 29,8 millions de dollars (+239 % en glissement annuel) et un bénéfice d'exploitation non-GAAP de 57,0 millions de dollars.
Les points forts incluent un nombre record de nouvelles prescriptions pour patients, une base de prescripteurs élargie et des taux d'arrêt plus faibles. BioCryst a effectué un remboursement de dette de 50 millions de dollars en juillet et prévoit de rembourser la totalité de sa dette à terme restante grâce aux revenus issus de la vente de son activité européenne ORLADEYO. La société maintient ses prévisions de chiffre d'affaires ORLADEYO pour 2025 entre 580 et 600 millions de dollars et prévoit des flux de trésorerie positifs sur l'ensemble de l'année.
Le pipeline des maladies rares continue de progresser avec les granulés ORLADEYO pour enfants (date PDUFA : 12 décembre 2025) et les données initiales attendues des programmes BCX17725 et avoralstat d'ici la fin de l'année.
BioCryst Pharmaceuticals (Nasdaq:BCRX) meldete herausragende Finanzergebnisse für das zweite Quartal 2025 und verzeichnete damit das beste Quartal in der Firmengeschichte. Die Nettoumsätze von ORLADEYO erreichten 156,8 Millionen US-Dollar, ein Anstieg von 45 % im Jahresvergleich, bei einem Gesamtumsatz von 163,4 Millionen US-Dollar. Das Unternehmen erzielte einen operativen Gewinn von 29,8 Millionen US-Dollar (+239 % im Jahresvergleich) und einen Non-GAAP-operativen Gewinn von 57,0 Millionen US-Dollar.
Zu den wichtigsten Highlights zählen Rekordwerte bei neuen Patientenverschreibungen, eine erweiterte Verordnerbasis und niedrigere Abbruchraten. BioCryst tätigte im Juli eine Schuldenrückzahlung in Höhe von 50 Millionen US-Dollar und plant, die verbleibenden Terminschulden mit Erlösen aus dem Verkauf seines europäischen ORLADEYO-Geschäfts vollständig zu tilgen. Das Unternehmen bestätigt seine Umsatzprognose für ORLADEYO 2025 von 580 bis 600 Millionen US-Dollar und erwartet für das Gesamtjahr positive Cashflows.
Die Pipeline für seltene Krankheiten schreitet weiter voran, mit ORLADEYO-Granulat für Kinder (PDUFA-Datum: 12. Dezember 2025) sowie erwarteten ersten Daten aus den Programmen BCX17725 und Avoralstat bis Jahresende.
- Record-breaking Q2 ORLADEYO revenue of $156.8M (+45% y-o-y)
- Operating profit of $29.8M (+239% y-o-y); non-GAAP operating profit $57.0M (+160% y-o-y)
- Highest-ever new patient prescriptions, beating launch quarter by 10%
- Lower patient discontinuation rates in H1 2025 vs H1 2024
- Strong cash position of $287.1M with $44.6M cash generated in Q2 (excluding debt payment)
- Plans to retire all remaining term debt from European business sale proceeds
- Increased R&D expenses to $43.4M (+15% y-o-y)
- Higher SG&A expenses at $87.4M (+43% y-o-y)
- Net cash utilization of $30.4M in Q2 due to debt prepayment
Insights
BioCryst shows exceptional Q2 performance with 45% YoY ORLADEYO revenue growth and plans to eliminate all term debt from European business sale proceeds.
BioCryst delivered an outstanding Q2 2025 with ORLADEYO generating
The company achieved record-breaking quarterly operating profit of
ORLADEYO's commercial strength is evidenced by multiple positive indicators: highest-ever quarterly new patient prescriptions (exceeding the launch quarter by
BioCryst's debt management strategy shows significant progress with a
The pipeline shows measured progress with pending pediatric ORLADEYO approval (PDUFA date: December 12, 2025) and two early-stage programs (BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema) expected to deliver initial data by year-end. While these programs represent future growth potential, the near-term valuation remains heavily dependent on ORLADEYO's continued success.
With
—Q2 2025 ORLADEYO net revenue of
—Q2 2025 operating profit of
—Company makes additional
RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
“The financial performance this quarter is the best in the company’s history resulting from better-than-expected revenue growth and very meaningful operating profit. In the fifth year since approval, ORLADEYO revenue and demand have never been stronger, and this is driven by outstanding execution and increasing confidence in the product. Our accelerating operating profit and the sale of our European ORLADEYO business strengthen our financial position to deliver even greater value, and our pipeline remains on track for initial data later this year in two clinical programs,” said Jon Stonehouse, chief executive officer of BioCryst.
ORLADEYO® (berotralstat): Oral, Once-daily Treatment for Prevention of Hereditary Angioedema (HAE) Attacks
- ORLADEYO net revenue in the second quarter of 2025 was
$156.8 million (+45 percent year-over-year (y-o-y)). - New patient prescriptions in the second quarter were the highest ever in a quarter, beating those in the first quarter of the launch by over 10 percent.
- The number of new prescribers of ORLADEYO in the U.S. in the second quarter increased to 69, up from 59 in the first quarter.
- Patient discontinuations in the U.S. were lower in the first half of 2025 than in the first half of 2024, despite the larger base of patients taking ORLADEYO.
- New real-world data from over 350 patients with HAE with normal C1 inhibitor showed substantial reductions in attack rates with ORLADEYO, reinforcing its value for a historically underserved patient segment and providing strong evidence to close both treatment and reimbursement gaps.
- Sales from the U.S. contributed 89.5 percent of global ORLADEYO net revenues in the second quarter.
“ORLADEYO continued its upward trajectory in the second quarter, delivering our strongest quarter yet for new patient prescriptions and revenue. Growth was fueled by increasing demand in the U.S. and internationally, improved efficiency in getting paid shipments, fewer discontinuations, gross-to-net improvements, and continued impact of our real-world evidence generation—especially for patients with HAE with normal C1 inhibitor. With this momentum, we are confident in meeting our prior full-year guidance, even when factoring in the expected removal of European ORLADEYO sales in the fourth quarter,” said Charlie Gayer, president and chief commercial officer of BioCryst.
Rare Disease Pipeline
Our goal is to build on our success with ORLADEYO by bringing additional selected, highly differentiated products to patients with rare diseases.
- The Prescription Drug User Fee Act goal date for the company’s new drug application for ORLADEYO granules in children with HAE aged 2 to 11 is December 12, 2025. ORLADEYO would be the first targeted oral prophylactic therapy for children with HAE.
- BCX17725, an investigational KLK5 inhibitor for the treatment of Netherton syndrome, is enrolling a phase 1 trial in healthy volunteers and patients. The company expects initial data from this program by the end of the year.
- Avoralstat, an investigational plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME), is enrolling a phase 1 trial in patients. The company expects initial data from this program by the end of the year.
Second Quarter 2025 Financial Results
For the three months ended June 30, 2025, total revenues were
Research and development expenses for the second quarter of 2025 increased to
Selling, general and administrative expenses for the second quarter of 2025 increased to
Operating income for the second quarter of 2025 was
Interest expense was
Net income for the second quarter of 2025 was
Cash, cash equivalents, restricted cash and investments totaled
In July, the company paid down an additional
Financial Outlook for 2025
The company is maintaining its outlook for full year 2025 global net ORLADEYO revenue to between
Excluding stock-based compensation expense and deal-related costs, and without removal of fourth quarter European operating expenses, the company expects 2025 non-GAAP operating expenses to be between
The company remains on track to deliver net income and positive cash flows for full year 2025. Positive cash flow refers to the improvement in cash, cash equivalents, restricted cash and investments from year end 2024 to year end 2025, not including the impact of
Conference Call and Webcast
BioCryst management will host a conference call and webcast at 8:30 a.m. ET today to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements, expectations regarding pipeline development timing, and statements related to the anticipated sale of BioCryst’s European ORLADEYO business (the “Transaction”), including financial estimates and statements as to the expected timing, completion and effects of the Transaction. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance, achievements or pipeline development timing to be materially different from any future results, performance, achievements, or timing expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions, including assumptions related to the expected date of closing of the Transaction and the potential benefits thereof, and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst’s ability to successfully progress its pipeline development plans as described herein, including meeting the expected timelines; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance and demand; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its products and product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; timing for achieving and sustainability of profitability and positive cash flow may not meet management’s expectations; statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and BioCryst’s ability to execute its operational and budget plans; actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management’s expected ranges; the benefits of the Transaction, including future financial and operating results; the completion of the Transaction on anticipated terms and timing, including obtaining required regulatory approvals, and the satisfaction of other conditions to the completion of the Transaction; the risk that disruptions from the Transaction will harm BioCryst’s business, including current plans and operations; potential adverse reactions or changes to business relationships resulting from the completion of the Transaction; potential business uncertainty, including changes to existing business relationships, during the pendency of the Transaction that could affect BioCryst’s financial performance; certain restrictions during the pendency of the Transaction that may impact BioCryst’s ability to pursue certain business opportunities or strategic transactions; significant transaction costs associated with the Transaction; the possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; the occurrence of any event, change or other circumstance that could give rise to the termination of the Transaction; and competitive responses to the Transaction. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.
Non-GAAP Financial Measures
The information furnished in this release includes non-GAAP financial measures that differ from measures calculated in accordance with generally accepted accounting principles in the United States of America (“GAAP”), including financial measures labeled as “non-GAAP” or “adjusted.”
We believe providing these non-GAAP measures, which show our results with these items adjusted, is valuable and useful since they allow management and investors to better understand the company’s financial performance in the absence of certain non-cash items such as stock-based compensation and special events and allow investors to more accurately understand our current and past period results and more easily compare them to future results. These non-GAAP measures also correspond with the way we expect investors and financial analysts to compare our results. Our non-GAAP measures should be considered only as supplements to, and not as substitutes for or in isolation from, our other measures of financial information prepared in accordance with GAAP, such as GAAP revenue, operating income, net income, and earnings per share.
Our references to the “non-GAAP” or “adjusted” financial measures of non-GAAP operating expenses, non-GAAP operating income (loss), non-GAAP net income (loss), and non-GAAP net income (loss) per common share for the three and six months ended June 30, 2024 and June 30, 2025 constitute non-GAAP financial measures. For 2024, it refers to our GAAP results, adjusted to show the results without including non-cash stock compensation expense. For 2025, it refers to our GAAP results, adjusted to show the results without including non-cash stock compensation expense and deal-related costs in connection with the anticipated sale of the company’s European ORLADEYO business. A reconciliation between GAAP and non-GAAP operating expenses, non-GAAP operating income (loss) and non-GAAP net income (loss) is provided in the table below.
We also provide our non-GAAP operating expense outlook for full year 2025, which refers to our expected GAAP operating expense, excluding stock-based compensation expense and deal-related costs. We have not provided a reconciliation against the comparable forward-looking GAAP measure because we are unable to predict with reasonable certainty the full amount of stock-based compensation expense or deal-related costs for the full year 2025 without unreasonable effort. Stock-based compensation expense is uncertain and depends on various factors, including our future hiring and retention needs, as well as the future fair market value of our common stock, which is difficult to predict and subject to change. In addition, we are unable to predict with reasonable certainty the full amount of deal-related costs as the closing of the sale of our European business is still pending and the related costs are dependent on various factors that have not yet occurred. The actual amount of stock-based compensation expense and deal-related costs for the full year 2025 could have a material impact on GAAP reported results for the guidance period.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
| BIOCRYST PHARMACEUTICALS, INC. | |||||||||||||||
| CONSOLIDATED FINANCIAL SUMMARY | |||||||||||||||
| (In thousands, except per share) | |||||||||||||||
| Statements of Operations (Unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenues: | |||||||||||||||
| ORLADEYO | $ | 156,837 | $ | 108,288 | $ | 291,080 | $ | 197,155 | |||||||
| Other | 6,516 | 1,044 | 17,807 | 4,938 | |||||||||||
| Total revenues | 163,353 | 109,332 | 308,887 | 202,093 | |||||||||||
| Expenses: | |||||||||||||||
| Cost of product sales | 2,798 | 1,699 | 7,366 | 2,964 | |||||||||||
| Research and development | 43,386 | 37,623 | 80,656 | 84,116 | |||||||||||
| Selling, general and administrative | 87,383 | 61,249 | 169,852 | 120,740 | |||||||||||
| Total operating expenses | 133,567 | 100,571 | 257,874 | 207,820 | |||||||||||
| Income (loss) from operations | 29,786 | 8,761 | 51,013 | (5,727 | ) | ||||||||||
| Other income (expense): | |||||||||||||||
| Interest income | 2,516 | 3,554 | 5,540 | 7,585 | |||||||||||
| Interest expense | (21,582 | ) | (24,733 | ) | (45,076 | ) | (49,239 | ) | |||||||
| Foreign currency losses, net | (63 | ) | (84 | ) | (62 | ) | (135 | ) | |||||||
| Loss on extinguishment of debt | (4,171 | ) | — | (4,171 | ) | — | |||||||||
| Total other expense | (23,300 | ) | (21,263 | ) | (43,769 | ) | (41,789 | ) | |||||||
| Income (loss) before income taxes | 6,486 | (12,502 | ) | 7,244 | (47,516 | ) | |||||||||
| Income tax expense | 1,401 | 172 | 2,127 | 537 | |||||||||||
| Net income (loss) | $ | 5,085 | $ | (12,674 | ) | $ | 5,117 | $ | (48,053 | ) | |||||
| Net income (loss) per common share: basic | $ | 0.02 | $ | (0.06 | ) | $ | 0.02 | $ | (0.23 | ) | |||||
| Weighted average shares of common stock outstanding: basic | 209,519 | 206,425 | 209,203 | 206,244 | |||||||||||
| Net income (loss) per common share: diluted | $ | 0.02 | $ | (0.06 | ) | $ | 0.02 | $ | (0.23 | ) | |||||
| Weighted average shares of common stock outstanding: diluted | 219,886 | 206,425 | 217,574 | 206,244 | |||||||||||
| Balance Sheet Data (in thousands) | |||||||
| June 30, 2025 | December 31, 2024 | ||||||
| (unaudited) | Note 1 | ||||||
| Cash, cash equivalents and investments | $ | 270,139 | $ | 341,173 | |||
| Restricted cash | 1,892 | 1,610 | |||||
| Receivables | 91,177 | 79,069 | |||||
| Current assets held for sale (Note 2) | 29,170 | — | |||||
| Total assets | 457,188 | 490,420 | |||||
| Secured term loan | 242,794 | 314,869 | |||||
| Royalty financing obligation | 483,583 | 513,729 | |||||
| Accumulated deficit | (1,764,923 | ) | (1,770,040 | ) | |||
| Stockholders’ deficit | (421,594 | ) | (475,934 | ) | |||
| Shares of common stock outstanding | 209,905 | 208,543 | |||||
| Note 1: Derived from audited financial statements. | |||||||
| Note 2: Current assets held for sale include the assets of the Company’s European ORLADEYO Business, primarily comprised of | |||||||
| Reconciliation of Non-GAAP Operating Expenses, Non-GAAP Income from Operations, Non-GAAP Net Income (Loss), and Non-GAAP Earnings (Loss) Per Share (in thousands, except per share) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| As reported GAAP operating expenses | $ | 133,567 | $ | 100,571 | $ | 257,874 | $ | 207,820 | |||||||
| Less: Deal costs related to sale of European business | 5,888 | — | 6,438 | — | |||||||||||
| Less: Stock-based compensation expense | 21,304 | 13,173 | 42,672 | 26,825 | |||||||||||
| Non-GAAP operating expenses | $ | 106,375 | $ | 87,398 | $ | 208,764 | $ | 180,995 | |||||||
| GAAP income (loss) from operations | $ | 29,786 | $ | 8,761 | $ | 51,013 | $ | (5,727 | ) | ||||||
| Less: Deal costs related to sale of European business | (5,888 | ) | — | (6,438 | ) | — | |||||||||
| Less: Stock-based compensation expense | (21,304 | ) | (13,173 | ) | (42,672 | ) | (26,825 | ) | |||||||
| Non-GAAP income from operations | $ | 56,978 | $ | 21,934 | $ | 100,123 | $ | 21,098 | |||||||
| GAAP net income (loss) | $ | 5,085 | $ | (12,674 | ) | $ | 5,117 | $ | (48,053 | ) | |||||
| Less: Deal costs related to sale of European business | (5,888 | ) | — | (6,438 | ) | — | |||||||||
| Less: Stock-based compensation expense | (21,304 | ) | (13,173 | ) | (42,672 | ) | (26,825 | ) | |||||||
| Non-GAAP net income (loss) | $ | 32,277 | $ | 499 | $ | 54,227 | $ | (21,228 | ) | ||||||
| GAAP basic net income (loss) per common share | $ | 0.02 | $ | (0.06 | ) | $ | 0.02 | $ | (0.23 | ) | |||||
| GAAP diluted net income (loss) per common share | $ | 0.02 | $ | (0.06 | ) | $ | 0.02 | $ | (0.23 | ) | |||||
| Non-GAAP basic net income (loss) per common share | $ | 0.15 | $ | 0.00 | $ | 0.26 | $ | (0.10 | ) | ||||||
| Non-GAAP diluted net income (loss) per common share | $ | 0.15 | $ | 0.00 | $ | 0.25 | $ | (0.10 | ) | ||||||
FAQ
What were BioCryst's (BCRX) Q2 2025 ORLADEYO sales?
How much operating profit did BioCryst report in Q2 2025?
What is BioCryst's revenue guidance for ORLADEYO in 2025?
How much debt did BioCryst pay down in 2025?
What is the status of BioCryst's pipeline programs?
